#Sweden #Immunovia #Lund #pancreatic cancer #warrants exercise

Immunovia AB Concludes Warrant Series TO 2 Exercise Successfully

LUND, Sweden – On January 20, 2025, Immunovia AB announced the conclusion of its warrant exercise period for the series TO 2. This exercise, which ended on January 16, 2025, saw an impressive uptake, with 92,197,387 warrants exercised, representing approximately 74.1 percent of the total warrants available. As a result, no additional guarantee commitments were required, setting a positive tone for the company’s ongoing initiatives.

CEO Jeff Borcherding expressed gratitude to the investors, stating, "We appreciate the investment in Immunovia by those who exercised warrants. We plan to utilize this capital strategically to ready our next-generation test for the U.S. market, projected for release later this year. This capital will also support the generation of further clinical data required for test reimbursement."

The exercise period was open from January 2 to January 16, where each warrant could be exchanged for one new share at a subscription price of SEK 0.46. With the successful exercise, Immunovia will receive approximately 42.4 million SEK before any issue costs are deducted.

Overview of Share Adjustments

The completion of the warrant exercise will increase Immunovia's total shares from 169,711,476 to 261,908,863. Consequently, the share capital will rise by SEK 2,765,921.61, reaching a total of SEK 7,857,265.89. Existing shareholders who did not exercise their warrants will experience a dilution of around 35.2 percent, a significant figure considering the scale of new shares introduced.

Interim shares (IA) have been issued to represent the exercised warrants pending their formal registration with the Swedish Companies Registration Office. These interim shares are anticipated to convert to full shares within approximately two weeks.

Advising Partners

In this significant corporate action, Vator Securities AB served as the financial adviser, while Setterwalls acted as the legal adviser to Immunovia. Vator also took on the role of issuing agent, further showcasing the importance of this successful warrant exercise.

Looking Ahead for Immunovia

Immunovia AB is on a crucial mission to improve survival rates for patients with pancreatic cancer through earlier detection. With a robust focus on developing and commercializing simplified blood-based testing solutions, the company aims to identify proteins and antibodies that signal a high risk of pancreatic cancer.

Given that the U.S. market represents the largest potential for pancreatic cancer detection, with an estimated 1.8 million high-risk individuals, Immunovia is positioning itself to provide vital annual surveillance testing. Its shares are listed on Nasdaq Stockholm under the ticker IMMNOV.

For more company insights, visit Immunovia's official website.

Important Note

The information in this report does not constitute an offer to acquire or trade shares or other securities in Immunovia. The invitation to subscribe for shares and warrants was solely through the prospectus published on August 12, 2024, which was duly approved by the Swedish Financial Supervisory Authority.

As Immunovia continues its essential services in accordance with the Swedish Screening of Foreign Direct Investment Act, the exercise of warrants will undergo necessary review processes as stipulated. Updates will be made available on the website as required.